Large Commercial Payer Adds Phexxi® to Formulary for Standard Plans Nationwide

Stock Information for Evofem Biosciences Inc.

Loading

Please wait while we load your information from QuoteMedia.

More Recent News About Evofem Biosciences Inc.

Evofem Biosciences to Present at the OTCQB Venture Virtual Investor Conference on August 1st
Evofem Signs Phexxi® License Agreement for Middle East with Pharma 1
Aditxt and Evofem Amend and Restate Merger Agreement, Targeting September 30 Closing
Hello Alpha Partners with Evofem to Offer Phexxi® as a Hormone-Free Contraception Solution on its Platform for Women's Healthcare
Evofem Announces Issuance of New U.S. Patent Covering Phexxi Composition of Matter
Evofem Biosciences Announces Financial Results for the First Quarter of 2024
Evofem Strengthens Phexxi Intellectual Property with New Composition of Matter Patent From USPTO
Evofem Reports $18.2 million of Phexxi Net Product Sales in 2023

Market data content copyright © QuoteMedia. Data delayed at least 15 minutes unless otherwise indicated (view Delay Times for all exchanges). Filings and Fundamentals by Morningstar. Insiders by Morningstar (USA) and SEDI (CDN). Analyst ratings by Zacks. Terms of Use.